Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Neoadjuvant Therapy for Esophageal Adenocarcinoma in the Community Setting-Practice and Outcomes.

Abdo J, Bertellotti CA, Cornell DL, Agrawal DK, Mittal SK.

Front Oncol. 2017 Jul 18;7:151. doi: 10.3389/fonc.2017.00151. eCollection 2017.

2.

A multifactorial 'Consensus Signature' by in silico analysis to predict response to neoadjuvant anthracycline-based chemotherapy in triple-negative breast cancer.

Turner N, Forcato M, Nuzzo S, Malorni L, Bicciato S, Di Leo A.

NPJ Breast Cancer. 2015 Jun 2;1:15003. doi: 10.1038/npjbcancer.2015.3. eCollection 2015.

3.

"Targeted" Chemotherapy for Esophageal Cancer.

Abdo J, Agrawal DK, Mittal SK.

Front Oncol. 2017 Apr 3;7:63. doi: 10.3389/fonc.2017.00063. eCollection 2017. No abstract available.

4.

Basis for molecular diagnostics and immunotherapy for esophageal cancer.

Abdo J, Agrawal DK, Mittal SK.

Expert Rev Anticancer Ther. 2017 Jan;17(1):33-45. Epub 2016 Nov 23. Review.

PMID:
27838937
5.

Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.

Hergueta-Redondo M, Sarrio D, Molina-Crespo Á, Vicario R, Bernadó-Morales C, Martínez L, Rojo-Sebastián A, Serra-Musach J, Mota A, Martínez-Ramírez Á, Castilla MÁ, González-Martin A, Pernas S, Cano A, Cortes J, Nuciforo PG, Peg V, Palacios J, Pujana MÁ, Arribas J, Moreno-Bueno G.

Oncotarget. 2016 Aug 30;7(35):56295-56308. doi: 10.18632/oncotarget.10787.

6.

The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells.

Hansen SN, Ehlers NS, Zhu S, Thomsen MB, Nielsen RL, Liu D, Wang G, Hou Y, Zhang X, Xu X, Bolund L, Yang H, Wang J, Moreira J, Ditzel HJ, Brünner N, Schrohl AS, Stenvang J, Gupta R.

BMC Genomics. 2016 Jun 9;17:442. doi: 10.1186/s12864-016-2749-4.

7.

Triple-negative breast cancer exhibits a favorable response to neoadjuvant chemotherapy independent of the expression of topoisomerase IIα.

Nogi H, Uchida K, Kamio M, Kato K, Toriumi Y, Akiba T, Morikawa T, Suzuki M, Kobayashi T, Takeyama H.

Mol Clin Oncol. 2016 Mar;4(3):383-389. Epub 2015 Dec 21.

8.

Dissecting GRB7-mediated signals for proliferation and migration in HER2 overexpressing breast tumor cells: GTP-ase rules.

Pradip D, Bouzyk M, Dey N, Leyland-Jones B.

Am J Cancer Res. 2013 Apr 3;3(2):173-95. Print 2013.

9.

Pathological tumor response to neoadjuvant chemotherapy using anthracycline and taxanes in patients with triple-negative breast cancer.

Sakuma K, Kurosumi M, Oba H, Kobayashi Y, Takei H, Inoue K, Tabei T, Oyama T.

Exp Ther Med. 2011 Mar;2(2):257-264. Epub 2011 Jan 20.

10.

Prognostic significance of TOP2A gene dosage in HER-2-negative breast cancer.

Zaczek AJ, Markiewicz A, Seroczynska B, Skokowski J, Jaskiewicz J, Pienkowski T, Olszewski WP, Szade J, Rhone P, Welnicka-Jaskiewicz M, Jassem J.

Oncologist. 2012;17(10):1246-55. doi: 10.1634/theoncologist.2012-0023. Epub 2012 Aug 7.

11.

APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer.

Brough R, Bajrami I, Vatcheva R, Natrajan R, Reis-Filho JS, Lord CJ, Ashworth A.

EMBO J. 2012 Mar 7;31(5):1160-76. doi: 10.1038/emboj.2011.490. Epub 2012 Jan 31.

12.

Potential utility of an expression array signature for predicting anthracycline responsiveness or resistance.

Press MF, Gordon MA, Slamon DJ.

J Clin Oncol. 2012 Feb 1;30(4):357-61. doi: 10.1200/JCO.2011.35.1023. Epub 2011 Dec 27. No abstract available.

13.

TOP2A amplification in the absence of that of HER-2/neu: toward individualization of chemotherapeutic practice in breast cancer.

Glynn RW, Mahon S, Curran C, Callagy G, Miller N, Kerin MJ.

Oncologist. 2011;16(7):949-55. doi: 10.1634/theoncologist.2011-0071. Epub 2011 Jun 24.

14.

Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization.

Romero A, Martín M, Cheang MC, López García-Asenjo JA, Oliva B, He X, de la Hoya M, García Sáenz JÁ, Arroyo Fernández M, Díaz Rubio E, Perou CM, Caldés Llopis T.

Am J Pathol. 2011 Apr;178(4):1453-60. doi: 10.1016/j.ajpath.2010.12.042. Review.

15.

Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers.

Lamy PJ, Fina F, Bascoul-Mollevi C, Laberenne AC, Martin PM, Ouafik L, Jacot W.

Breast Cancer Res. 2011 Feb 2;13(1):R15. doi: 10.1186/bcr2824.

16.
17.

High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer.

Staaf J, Jönsson G, Ringnér M, Vallon-Christersson J, Grabau D, Arason A, Gunnarsson H, Agnarsson BA, Malmström PO, Johannsson OT, Loman N, Barkardottir RB, Borg A.

Breast Cancer Res. 2010;12(3):R25. doi: 10.1186/bcr2568. Epub 2010 May 6.

18.

Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma.

Gruver AM, Peerwani Z, Tubbs RR.

J Clin Pathol. 2010 Mar;63(3):210-9. doi: 10.1136/jcp.2009.062760. Review.

19.

Aberrations of ERBB2 and TOP2A genes in breast cancer.

Nielsen KV, Müller S, Møller S, Schønau A, Balslev E, Knoop AS, Ejlertsen B.

Mol Oncol. 2010 Apr;4(2):161-8. doi: 10.1016/j.molonc.2009.11.001. Epub 2009 Nov 18.

20.

Genetic characterization of breast cancer and implications for clinical management.

Geyer FC, Lopez-Garcia MA, Lambros MB, Reis-Filho JS.

J Cell Mol Med. 2009 Oct;13(10):4090-103. doi: 10.1111/j.1582-4934.2009.00906.x. Epub 2009 Sep 14. Review.

Supplemental Content

Support Center